Clearer evidence for immune surveillance in malignancy and the identification of many new
tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted …

The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or …

Tumors often upregulate the expression of molecules that are normally suppressed or
expressed at much lower levels in adult tissues, the so-named tumor-associated antigens …

The clinical goal of tumour immunotherapy is to provide either active or passive immunity
against malignancies by harnessing the immune system to target tumours. Although …

The clinical application of immunotherapy for cancer is rapidly moving forward in multiple
areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of …

The last 10 years have seen a growth in the number of tumour antigens identified from
immune responses raised in patients. The discovery that tumours can be recognised by the …

Over the last decade, since the pioneering work resulting in the molecular cloning of the first
human tumour antigen using tumour cell expression libraries selected by tumour-specific T …

These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy
of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic …

The critical role of antigen-specific T cells in the eradication of cancer has been
demonstrated in numerous animal models. Data compiled from both in vitro systems and …

Therapeutic vaccines for the treatment of cancer aim to induce or boost T-cell immunity
against tumor-specific or tumor-associated antigens when it is has failed to develop naturally …